Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$44.04
-$1.27(-2.19%)
At close: 4:00 PM EDT
$44.04
-$1.27(-2.19%)
Day’s Range― - ―
52-Week Range$29.46 - $60.91
Previous Close$55.6
Volume589.88K
Average Volume (3M)1.37M
Market Cap
$3.42B
Enterprise Value$4.37K
Total Cash (Recent Filing)$485.23M
Total Debt (Recent Filing)$40.11M
Price to Earnings (P/E)29.5
Beta1.08
Next Earnings
Nov 10, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.44
Shares Outstanding80,390,730
10 Day Avg. Volume1,290,885
30 Day Avg. Volume1,373,650
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$58.14Price Target Upside32.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)1.9
Revenue Forecast (FY)$593.64M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Profitability InflectionVeracyte has expanded revenue substantially while moving from historical losses to durable profitability. Strong gross margins indicate valuable diagnostic offerings and provide operating leverage as testing volumes and commercial adoption continue to scale.
Strong Cash GenerationRecent earnings are converting efficiently into cash, giving Veracyte internally funded capacity for research, commercialization, infrastructure, or acquisitions. This reduces reliance on external financing and strengthens resilience as the business grows.
Conservative Balance SheetVery low leverage limits interest and refinancing risk while preserving financial flexibility. Veracyte can invest in assay development, laboratory capacity, and market expansion without the balance-sheet constraints that affect more indebted peers.
Bears Say
Growth Is ModeratingDecelerating growth raises the risk that Veracyte’s current profitability improvement will not be supported by sustained operating expansion. Slower adoption or market maturation could reduce leverage from its fixed laboratory and commercial infrastructure.
Testing Revenue And Reimbursement ConcentrationDependence on test volume and reimbursement creates structural concentration risk. Changes in payer coverage, coding, payment rates, or clinician utilization could pressure revenue per test, collections, and the ability to monetize investments in new assays.
Profitability Scaling Remains IncompleteThe recent earnings and cash-flow improvement is encouraging, but the history shows that profitability has not yet been proven across cycles. Moderate returns on the expanding equity base suggest further execution is needed to achieve consistently high capital efficiency.
Veracyte News
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $29.45 and its highest was $60.91 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $3.42B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Nov 10, 2026 which is in 65 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Jul 30, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.41.
How many shares outstanding does Veracyte have?
Veracyte has 80,390,730 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.54 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went down -22.516%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$58.14 (32.02% Upside)
$58.14 (32.02% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 464.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veracyte
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$58.14
▲(32.02% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.77% Insiders
34.08% Mutual Funds
22.03% Other Institutional Investors
6.67% Public Companies and
Individual Investors